A 52-year-old woman presents with a 6-month history of episodic vertigo lasting 30–45 minutes, accompanied by tinnitus, aural fullness, and fluctuating hearing loss in the right ear. Pure-tone audiometry shows the pattern marked **A** in the diagram. Based on the audiometric findings and clinical presentation, which of the following is the MOST APPROPRIATE first-line management?
A. Strict sodium restriction (≤1500 mg/day) and hydrochlorothiazide-triamterene diuretic therapy
B. Vestibular neurectomy to preserve hearing while controlling vertigo
C. Betahistine monotherapy without dietary modification
D. Intratympanic gentamicin injection for chemical labyrinthectomy
Explanation
Why Option 1 is correct
The pattern marked A — low-frequency asymmetric sensorineural hearing loss — is the hallmark audiometric finding in Ménière disease caused by endolymphatic hydrops. Combined with the clinical tetrad (episodic vertigo, fluctuating hearing loss, tinnitus, aural fullness), this confirms Ménière disease. According to AAO-HNS guidelines and Dhingra ENT, the stepwise management begins with LIFESTYLE modification (strict sodium restriction ≤1500 mg/day, reduced caffeine/alcohol/nicotine) and FIRST-LINE PHARMACOLOGIC therapy with thiazide or thiazide-like diuretics (hydrochlorothiazide-triamterene 25/37.5 mg daily). This addresses the underlying pathophysiology of endolymphatic hydrops by promoting fluid homeostasis and is attempted before any invasive intervention.
Why each distractor is wrong
Option 2 (Intratympanic gentamicin): Gentamicin is a chemical labyrinthectomy reserved for REFRACTORY cases after failure of medical therapy and only in unilateral disease with serviceable contralateral hearing. It controls vertigo (80–90%) but risks further hearing loss — premature use in a newly diagnosed patient violates the stepwise approach.
Option 3 (Vestibular neurectomy): This is a SURGICAL option reserved for advanced, medically refractory disease. It preserves hearing but is not first-line and requires failure of medical management and consideration of patient age and comorbidities.
Option 4 (Betahistine monotherapy): While betahistine (24 mg TDS) is widely used outside the US, it is NOT first-line monotherapy in the stepwise algorithm. Sodium restriction and diuretics form the foundation; betahistine may be added as adjunctive therapy but does not address the fluid homeostasis defect as directly.
High-YieldNEET PG
Ménière disease = endolymphatic hydrops; first-line = sodium restriction + thiazide diuretics; intratympanic gentamicin only after medical failure in unilateral disease.
Dhingra ENT 8e; Cummings Otolaryngology 7e; AAO-HNS Clinical Practice Guideline 2020
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
